🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Meet Bharat Reddy, PhD, Principal Scientist on #TeamRectify! With deep #StructuralBiology experience, a key pillar of the #PFM platform, Bharat plays a critical role in our mission to rectify membrane protein dysfunction that drive disease. More about us: bit.ly/3V5Vul7

February is #RareDiseaseMonth. Many rare diseases stem from disruptions in essential cellular processes, like protein receptor function. Learn more about our work to advance meaningful solutions for patients with rare disease here: bit.ly/408DwTh

Our CEO, Rajesh Devraj, & CMO, Pol Boudes, spoke to the @ClinicalTrialVG about the vital role of membrane-bound proteins like #ABCTransporters and how we are addressing unmet medical needs through innovation with our #PFMs. Read more: clinicaltrialvanguard.com/executiveinter…

#Rare doesn't mean alone! This #RareDiseaseDay, we stand with the #PrimarySclerosingCholangitis (PSC) community and advocates such as PSC Partners Seeking a Cure, who work tirelessly to create a better future for those living with #PSC. More here: bit.ly/3QvGkUe

Our CEO, Rajesh Devraj, joined the Xtalks Webinars podcast to discuss oral, small molecule #PFMs for diseases caused by membrane protein dysfunction, drug discovery challenges & their impact on #PSC, #CKD, & neurodegenerative disorders. ⬇️ Listen down below!

#ICYMI: Our CMO, Pol Boudes, MD, joined Pharma Technology Focus to discuss refined patient categorization & innovative diagnostics for #MASH. His insightful discussion paves the way for more effective trials & less invasive fibrosis staging. ​ ​Read more here: bit.ly/4kKotqz

We're proud to have Youhwa Jo on our team. As a Senior Research Associate II, she tackles scientific challenges with grit & urgency, executing assays & studies with rigor.She's also a supportive, collaborative colleague whose commitment to innovation makes a difference every day!

Rectify President & CEO Rajesh Devraj joins Rahul Chaturvedi on this week’s episode of #Biotech2050 to share how we’re rethinking small-molecule drug development—starting with RTY-694 for PSC. Listen now: on.soundcloud.com/du1dNd1TXkhNyT…

Join our CMO, Pol Boudes, at the Chief Medical Officer Summit 360˚next month! He’ll discuss optimizing clinical trials through streamlined operations and connects with CMOs across indications, modalities, company stages, & more. Learn more: cmosummit360.com #CMO360

Proud to see our work featured in Communications Biology! The study provides structural insights into mutation-driven BSEP misfolding & dysfunction, advancing our development of #PFMs for #PrimarySclerosingCholangitis, PFIC2 & related conditions. More here:bit.ly/42yoo29

Our pipeline of #PositiveFunctionalModulators is set to revolutionize treatment by restoring membrane protein function. Our #PFMs target programs in #hepatobiliary, #cardiorenal, & #neurodegenerative conditions, offering renewed hope. Learn more: bit.ly/3V5Vul7

Dr. Eric Bell will present on our lead program #PrimarySclerosingCholangitis at #EASLCongress 2025 during the Immune-mediated & Cholestatic Diseases session. We look forward to engaging with experts & sharing insights on advancing treatments. Read more: bit.ly/3Go6eHS

At #EASLCongress 2025 we’re presenting data that demonstrates the potential for a B4/BSEP PFM to address the core pathology of multiple liver & biliary diseases, incl. #PrimarySclerosingCholangitis. Read more: bit.ly/4m8O2lP

We’re attending the 62nd ERA - European Renal Association Congress June 4–7! We’ll present new transitional data from our cardio-renal-metabolic program addressing critical unmet needs in kidney health. More on our presentation: bit.ly/4kvrMRM #ERA25

#DYK Healthy bile flow and composition are key to #BiliaryHealth—supporting digestion, waste removal, and protecting the liver. Disruptions, especially in bile salts and phospholipids, are central to diseases like #PrimarySclerosingCholangitis. Learn more: bit.ly/3V5Vul7

We’re presenting at the 62nd ERA - European Renal Association Congress! Our translational data on ABCC6-targeting #PFM for chronic kidney disease & vascular calcification, a key driver of morbidity in cardiovascular disease. Join us at the CKD session! More info here:bit.ly/45KIhoF

#ICYMI: Our CEO, Rajesh Devraj, joined Sam Kessel on the Nucleate podcast to talk target validation, PFMs, and the mission driving Rectify’s work in #PSC and beyond. 🎧 Tune in: bit.ly/4dYMuqQ

We presented at the 62nd ERA - European Renal Association Congress, sharing translational data on our ABCC6-targeting #PFM for chronic kidney disease and vascular calcification, key drivers of cardiovascular morbidity. Missed it? View the presentation here: bit.ly/4jPuErQ #CKD

Are you attending Biotechnology Innovation Organization #BIO2025 in Boston? Our team is excited to connect with global industry leaders at this premier event. Let’s connect!​ 📢 Learn more: bit.ly/3HBQl11

#ICYMI: Our CEO, Rajesh Devraj, joined Sam Kessel on the Nucleate podcast to talk target validation, PFMs, and the mission driving Rectify’s work in #PSC and beyond.​ 🎧 Tune in: bit.ly/3ZVPPRJ